Covered recipient · General Payments record
CARMEN A HOWE
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2024
$339.64
- Reported across 16 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $339.64 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Braeburn Inc. | $64.01 | 3 |
| Indivior Inc. | $63.09 | 2 |
| Novo Nordisk AS | $61.42 | 3 |
| ABBVIE INC. | $55.09 | 3 |
| Lilly USA, LLC | $55.04 | 3 |
| ITI, Inc. | $21.39 | 1 |
| Vanda Pharmaceuticals Inc. | $19.60 | 1 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2024 | $339.64 | 16 |
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $19.41 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107362287 | CMS |
| ABBVIE INC. | $21.98 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107362289 | CMS |
| ABBVIE INC. | $13.70 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107362291 | CMS |
| Braeburn Inc. | $14.91 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125611057 | CMS |
| Braeburn Inc. | $23.60 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125611059 | CMS |
| Braeburn Inc. | $25.50 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125611061 | CMS |
| Indivior Inc. | $33.20 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144556469 | CMS |
| Indivior Inc. | $29.89 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144556471 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.39 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143504784 | CMS |
| Lilly USA, LLC | $17.08 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135615425 | CMS |
| Lilly USA, LLC | $18.54 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135577458 | CMS |
| Lilly USA, LLC | $19.42 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135583984 | CMS |
| Novo Nordisk Inc | $16.66 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100376865 | CMS |
| Novo Nordisk Inc | $20.51 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100469174 | CMS |
| Novo Nordisk Inc | $24.25 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100652921 | CMS |
| Vanda Pharmaceuticals Inc. | $19.60 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133948750 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2024
- Source files
- Dataset page · Bulk file · PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.